insights_auto
Outlook: 28.6% bullish·0.0% bearish
Go to analysischevron_right
INM:NASDAQ
InMed Pharmaceuticals Inc
$15.56
0.00%
(0.00) 1D
Nov 6, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for INM...
Mkt. cap
8.55M
Avg. vol.
7.77K
Volume
0.00
52-wk high
$23.30
52-wk low
$5.75
EPS
-$2.73
Beta
0.94
Shares outstanding
549.00K
No. of employees
6
Mkt. cap
8.55M
Avg. vol.
7.77K
Volume
0.00
52-wk high
$23.30
52-wk low
$5.75
EPS
-$2.73
Beta
0.94
Shares outstanding
549.00K
No. of employees
6
News stories
From web sources and news partners
Investing.com Canada
·
10 hours ago
Form 8K InMed Pharmaceuticals Inc. For: 9 November By Investing.com
The Manila Times
·
11 hours ago
Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing
TradingView
·
3 days ago
InMed Pharmaceuticals Completes Merger; Shares Expected to Trade as MTRI
About InMed Pharmaceuticals Inc
CEOEric A. Adams
Employees6
Founded1981
HeadquartersVancouver, British Columbia, Canada
SectorHealth Care
IndustryPharmaceutical industry
Websiteinmedpharma.com
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
No analyst ratings found. | |||||
Previous reportsAll values in CAD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 820.19K | - | - | - |
Cost of goods sold | 635.99K | - | - | - |
Cost of revenue | 635.99K | - | - | - |
Research and development expenses | 630.64K | 1.02M | 805.74K | 206.02K |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.62M | 1.74M | 2.36M | 1.80M |
Operating expense | 2.30M | 2.82M | 3.21M | 2.01M |
Total operating expenses | 2.94M | 2.82M | 3.21M | 2.01M |
Operating income | -2.12M | -2.82M | -3.21M | -2.01M |
Other non operating income | - | - | - | - |
EBT including unusual items | -2.03M | -2.79M | -4.84M | -2.00M |
EBT excluding unusual items | -2.03M | -2.79M | -3.19M | -2.00M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -2.03M | -2.97M | -5.84M | -2.33M |
Net profit margin | -247.29% | - | - | - |
Earnings per share | - | - | - | - |
Interest and investment income | 74.38K | 47.77K | 29.06K | 14.31K |
Interest expense | - | - | -10.70K | - |
Net interest expenses | 74.38K | 47.77K | 18.36K | 14.31K |
Depreciation and amortization charges | 53.20K | 51.71K | 48.36K | 168.00 |
EBITDA | -2.07M | -2.77M | -3.16M | -2.01M |
Gain or loss from assets sale | - | - | 7.14K | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events